Coverage
-
April 09, 2014
A Massachusetts federal court rejected a motion to dismiss a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks of iron deficiency treatment Feraheme, ruling Monday that the suit could continue in light of the First Circuit's reviving the case.
1 other articles on this case.
View all »